News
Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™
Data presented highlight efficacy of broad-spectrum antibiotic for the treatment of serious skin infections including MRSA
Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections, announced today that Baxdela™ (delafloxacin), an investigational, registration-phase anionic fluoroquinolone, will be the subject of six poster presentations at IDWeek 2016, held October 26-30 at the New Orleans Ernest N. Morial Convention Center. Baxdela is a unique fluoroquinolone with activity against a broad array of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).